V. R. Dneprovskii, A. Fedorova, D. Abramov, E. Volchkov, N. Myakova
{"title":"Molecular pathogenesis of T-lymphoblastic lymphoma","authors":"V. R. Dneprovskii, A. Fedorova, D. Abramov, E. Volchkov, N. Myakova","doi":"10.24287/1726-1708-2024-23-1-172-179","DOIUrl":null,"url":null,"abstract":" T-lymphoblastic lymphoma (T-LBL) is one of the most common non-Hodgkin lymphomas in children. According to the 2022 WHO classification, T-LBL and acute T-lymphoblastic leukemia are considered as a single disease since they both have T-cell precursors as a morphological substrate. In recent years, some progress has been made in the treatment of this disease, but the prognosis for relapses and refractory cases remains extremely unfavorable. One of the promising areas that can increase the effectiveness of therapy is the use of new treatment approaches that consider the molecular and biological features of this tumor. This review examines in detail the molecular aspects of the pathogenesis of T-LBL.","PeriodicalId":38370,"journal":{"name":"Pediatric Hematology/Oncology and Immunopathology","volume":"39 20","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology/Oncology and Immunopathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24287/1726-1708-2024-23-1-172-179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
T-lymphoblastic lymphoma (T-LBL) is one of the most common non-Hodgkin lymphomas in children. According to the 2022 WHO classification, T-LBL and acute T-lymphoblastic leukemia are considered as a single disease since they both have T-cell precursors as a morphological substrate. In recent years, some progress has been made in the treatment of this disease, but the prognosis for relapses and refractory cases remains extremely unfavorable. One of the promising areas that can increase the effectiveness of therapy is the use of new treatment approaches that consider the molecular and biological features of this tumor. This review examines in detail the molecular aspects of the pathogenesis of T-LBL.
T淋巴细胞淋巴瘤（T-LBL）是儿童最常见的非霍奇金淋巴瘤之一。根据 2022 年世界卫生组织的分类，T-LBL 和急性 T 淋巴细胞白血病被视为一种疾病，因为它们都以 T 细胞前体为形态学基质。近年来，该病的治疗取得了一些进展，但复发和难治性病例的预后仍极为不利。考虑到这种肿瘤的分子和生物学特征，采用新的治疗方法是提高治疗效果的一个有希望的领域。本综述详细探讨了T-LBL发病机制的分子方面。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
